copaydosingefficacyresourcesafety

THIS SITE IS INTENDED FOR US AUDIENCES ONLY

Oral Ulcers in Behçet's Disease

About Behçet’s Disease

Behçet’s Disease (BD) is also referred to as Behçet’s Syndrome1

Click arrow for more information

  • About BD
  • Oral Ulcers in BD
  • Treatment for Oral Ulcers in BD

Behçet’s Disease is a rare, chronic, multisystem inflammatory disorder1

Behçet’s Disease, also referred to as Behçet’s Syndrome, is classified as a variable vessel vasculitis.1

  • Multiple systems can be affected by BD, but it is often characterized by recurrent oral ulcers accompanied by lesions in other organ systems1
  • The International Study Group (ISG) criteria can be used to diagnose BD by the presence of recurrent oral ulceration plus at least 2 of the following: recurrent genital ulceration, eye lesions, skin lesions, or a positive result on pathergy testing2

A diagnosis of BD typically takes approximately 5 years from the onset of manifestations3

Prevalence of manifestations4

Recurrent oral ulcers are the hallmark manifestation of BD5

Oral ulcers can be bothersome and painful6,7

  • Present in 98% of patients diagnosed with BD3,4
  • Recurrent oral ulcers in BD can crop, be painful, and scar4,8
  • Diagnosis of BD with recurrent oral ulcers is complicated by a number of possible differential diagnoses, such as aphthous stomatitis or inflammatory bowel disease, among others9

Oral ulcers can present in 98% of patients with BD3,4

Major-type oral aphthous ulcer10

Oral aphthous ulcer11

Herpetiform ulceration11

Otezla is the first and only FDA-approved systemic therapy for oral ulcers associated with BD12

  • In BD, the efficacy of Otezla® (apremilast) was demonstrated based on the number and pain of oral ulcers
  • The most commonly reported adverse reactions (≥10%) for Otezla were diarrhea, nausea, headache, and upper respiratory tract infection

An oral, non-biologic systemic treatment for patients with oral ulcers associated with Behçet’s Disease12

References: 1. Leonardo NM, McNeil J. Int J Rheumatol. 2015;2015:945262. 2. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335(8697):1078-1080. 3. Alpsoy E, Donmez L, Onder M, et al. Br J Dermatol. 2007;157(5):901-906. 4. Yazici Y, Yazici H, eds. Behçet’s Syndrome. New York, NY: Springer; 2010:7-34. 5. Zeidan MJ, Saadoun D, Garrido M, et al. Autoimmun Highlights. 2016;7(1):4. 6. Alpsoy E. J Dermatol. 2016;43(6):620-632. 7. Melikoglu M, Melikoglu M. Acta Reumatol Port. 2014;39:46-53. 8. Bang D, Hur W, Lee ES, Lee S. J Dermatol. 1995;22(12):926-929. 9. Ambrose NL, Haskard DO. Nat Rev Rheumatol. 2013;9(2):79-89. 10. Lee S, Bang D, Lee ES, Sohn S, eds. Behçet’s Disease: A Guide to its Clinical Understanding Textbook and Atlas. Heidelberg, Germany: Springer-Verlag; 2001:19-50. 11. Gualtierotti R, Marzano AV, Spadari F, et al. J Clin Med. 2019;8(1):1-19; http://creativecommons.org/licenses/by/4.0/. 12. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc.

Indications & Important Safety Information

Please click here for Full Prescribing Information.

You are leaving the Otezla® (apremilast) website

Do you wish to leave this site?

Are You a Healthcare Professional?

.marketAccessModal .lineOne, .marketAccessModal .lineTwo { font-size: 44px; text-transform: none; margin-bottom: 10px; } .marketAccessModal .lineTwo { font-size: 42px; text-transform: none; } @media screen and (max-width: 450px) { .marketAccessModal .lineOne, .marketAccessModal .lineTwo { font-size: calc(15px + 7 * ((100vw - 325px) / 125)); } }
The FDA approves a new indication for Otezla® (apremilast) Learn more about this treatment option for your patients
EXPLORE